文献速递妇科产科生殖医学

胰高血糖素样肽-1受体激动剂在不孕症和妊娠人群中的作用

Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy.
PubMed 文献 · Obstet Gynecol · 2025-01-23

肥胖与不孕及不良妊娠结局相关,传统减重方式效果有限。新型减重药物胰高血糖素样肽-1受体激动剂(GLP-1 RA)可帮助减重,但妊娠期禁用。妇产科医生应与患者合作,在孕前、孕间和产后管理这些药物。

要点

  • 肥胖增加不孕风险并影响促排卵药物的反应。
  • 妊娠期肥胖增加自然流产、出生缺陷、妊娠期糖尿病、高血压疾病、剖宫产和死产风险。
  • GLP-1 RA可帮助减重但妊娠期禁用,需在孕前、孕间和产后管理。

核心结论

  • GLP-1 RA和靶向肠道激素的新药可帮助实现减重目标,但妊娠期禁用。
  • 妇产科医生应与患者合作,在孕前、孕间和产后管理这些药物。

主要发现

  • 肥胖与不孕相关,可能影响对促排卵药物的反应。
  • 妊娠期肥胖增加自然流产、出生缺陷、妊娠期糖尿病、妊娠期高血压疾病、剖宫产和死产的风险。
  • 仅改变生活方式减重并未改善结局。

临床怎么用

  • 妇产科医生应与患者合作,在孕前、孕间和产后管理GLP-1 RA等减重药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a chronic condition that causes significant morbidity and mortality in people in the United States and around the world. Traditional means of weight loss include diet, exercise, behavioral modifications, and surgery. New weight loss medications, glucagon-like peptide-1 receptor agonists, are revolutionizing the management of weight loss but have implications for fertility and pregnancy. Obesity is associated with infertility and may affect response to ovulation induction medications. In pregnancy, obesity increases the risks of spontaneous abortion, birth defects, gestational diabetes, hypertensive disorders of pregnancy, cesarean delivery, and stillbirth. Lifestyle changes alone for weight loss have not improved outcomes. Glucagon-like peptide-1 receptor agonists and new medications targeting gut hormones can help people achieve their weight loss goals but are contraindicated in pregnancy. Obstetrician-gynecologists should work with patients to manage these medications before they become pregnant, between pregnancies, and after delivery.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Finkle J, Brost BC. Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy. Obstet Gynecol. 2025. PMID: 39847778. doi:10.1097/AOG.0000000000005825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。